NCT05485155View on ClinicalTrials.gov

Zemaira Eosinophilic Esophagitis Pilot Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

January 31, 2026

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

Alpha-proteinase inhibitor

Intravenous infusion at 120 mg/kg body weight dose/week for 4 weeks for a total of 4 infusions.

Trial Locations (2)

20892

RECRUITING

The National Institutes of Health, Bethesda

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors

Collaborators (1)

CSL Behring
All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

lead

Children's Hospital Medical Center, Cincinnati

OTHER